FDA
-
-
-
-
-
-
-
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend t
-
-
-
-
-
-
-
Scilex (SCLX) Announces Consummation of Previously Announced Purchase of all Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
-
-
-
-
-
-
-
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone T
-
-
-
-
-
-
-
Sorrento Announces Launch of Voluntary Offering to Dividend Short Holders with Deadline to Participate by July 27, 2023
-
-
-
-
-
-
-
Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study
-
-
-
-
-
-
-
Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
-
-
-
-
-
-
-
Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Broker
-
331,769 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
